Valneva's Stock Rebounds 2.4% After a 38% Collapse Over a Week

Valneva's Stock Performance

Valneva's stock has declined by 37.96% over seven days and 24.55% over three months, indicating particularly intense selling pressure. The current price of 2.83 euros is significantly below the 50-day moving average of 4.27 euros and the 200-day average of 3.87 euros, reflecting a pronounced downward trend across all time horizons. The RSI, an indicator measuring the magnitude of recent price changes, has dropped to 25, a level that signals a marked oversold condition. Typically, a threshold under 30 indicates that the downward pressure has been particularly rapid and strong, which can sometimes precede temporary technical rebounds, as seen with the slight surge this Monday. The stock is now fluctuating around its technical support identified at 2.76 euros, which exactly matches Friday's closing price. The most significant resistance is at 5.08 euros, a considerable gap from the current levels.

Sector Performance

The European pharmaceutical and biotechnology sector shows mixed trajectories this Monday. Sanofi is down by 1.59% while UCB is up by 0.48%, illustrating the lack of a uniform sector dynamic that could alone explain Valneva's trajectory. The Franco-Austrian biotech, specializing in vaccines, was already undergoing a difficult phase over a year, with a decline of 13.68%. The monthly volatility of the stock remains high at 23.98%, reflecting the uncertainty surrounding the value. The negative beta of -0.10 also indicates a decoupling from major indices, making the stock less sensitive to general market movements. The next key dates on the financial calendar are the first-quarter results, scheduled for May 7, 2026, followed by the annual general meeting on June 1. These milestones will be focal points to assess the operational and financial trajectory of the group in the coming weeks.